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py more likely reflect distinct pharmacological properties of 
antidepressants rather than the clinical response. In patients 
with panic disorder, changes in neuroactive steroid compo-
sition have been observed opposite to those seen in depres-
sion. However, during experimentally induced panic induc-
tion either with cholecystokinine-tetrapeptide or sodium 
lactate, there was a pronounced decline in the concentra-
tions of 3  -reduced neuroactive steroids in patients with 
panic disorder, which might result in a decreased GABAergic 
tone. In contrast, no changes in neuroactive steroid concen-
trations could be observed in healthy controls with the ex-
ception of 3  ,5  -tetrahydrodeoxycorticosterone. The mod-
ulation of GABA A  receptors by neuroactive steroids might 
contribute to the pathophysiology of depression and anxi-
ety disorders and might offer new targets for the develop-
ment of novel anxiolytic compounds. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 In the past decades, considerable evidence has emerged 
that certain steroids not only act as transcription factors 
in the regulation of gene expression  [1] but may also alter 
neuronal excitability through interaction with specific 
neurotransmitter receptors  [2–5] . The term ‘neuroactive 
steroids’ has been adapted for steroids with these particu-
lar properties. Furthermore, a variety of neuroactive ste-
roids may be synthesized de novo from cholesterol in the 
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 Abstract 
 Certain neuroactive steroids modulate ligand-gated ion 
channels via non-genomic mechanisms. Especially 3  -re-
duced pregnane steroids are potent positive allosteric mod-
ulators of the   -aminobutyric acid type A (GABA A ) receptor. 
During major depression, there is a disequilibrium of 3  -re-
duced neuroactive steroids, which is corrected by clinically 
effective pharmacological treatment. To investigate wheth-
er these alterations are a general principle of successful an-
tidepressant treatment, we studied the impact of nonphar-
macological treatment options on neuroactive steroid 
concentrations during major depression. Neither partial 
sleep deprivation, transcranial magnetic stimulation, nor 
electroconvulsive therapy affected neuroactive steroid lev-
els irrespectively of the response to these treatments. These 
studies suggest that the changes in neuroactive steroid con-
centrations observed after antidepressant pharmacothera-
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brain without the aid of peripheral sources  [6] . These 
neuroactive steroids have been defined as ‘neurosteroids’ 
 [7] .
 The main precursor molecule for the synthesis of neu-
roactive steroids is pregnenolone which is a precursor for 
dehydroepiandrosterone (DHEA). Pregnenolone may 
also be converted into progesterone which may be further 
reduced into the 3  -pregnane metabolites 5  -dihydro-
progesterone (5  -DHP) and 5  -dihydrodeoxycortico-
sterone (5  -DHDOC). These molecules serve as precur-
sors for the so-called 3  -reduced neuroactive steroids 
3  ,5  -tetrahydroprogesterone (3  ,5  -THP; allopreg-
nanolone), 3  ,5  -tetrahydroprogesterone (3  ,5  -THP; 
5  -pregnan-3  -ol-20-one) and 3  ,5  -tetrahydrodeoxy-
corticosterone (3  ,5  -THDOC; 3  ,21-dihydroxy-5  -
pregnan-20-one; allotetrahydrodeoxycorticosterone). In 
particular, these 3  -reduced neuroactive steroids are po-
tent positive allosteric modulators of the   -aminobutyric 
acid type A (GABA A ) receptor because they increase the 
frequency and/or duration of openings of the GABA-gat-
ed chloride channel  [2, 4] . Thereby, 3  ,5  -THDOC de-
rives mainly from the adrenal gland and the synthesis of 
its precursor deoxycorticosterone (DOC) is under the 
control of corticotropin (ACTH) ( fig. 1 ). A detailed re-
view on steroid biosynthesis in the central nervous sys-
tem is given elsewhere  [8] . In view of their GABA-en-
hancing properties, such 3  -reduced neuroactive ste-
roids are of major interest for depression and anxiety 
disorders. In contrast, the sulfate esters of pregnenolone 
or DHEA display GABA-antagonistic properties  [9, 10] . 
Although the majority of studies have focused on
the modulatory potential of neuroactive steroids at the 
GABA A  receptor, also other receptors, for example the N-
methyl- D -aspartate-gated ion channel  [11] or the    1  re-
ceptor  [12] , may be a target for neuroactive steroids. How-
ever, in view of their GABA-enhancing properties, 
3  -reduced neuroactive steroids are of particular interest 
for neuropsychopharmacological research. Preclinical 
studies suggested that neuroactive steroids may modulate 
anxiety and depression-related behavior. Moreover, it has 
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been suggested that neuroactive steroids may be involved 
in the therapeutical effects of antidepressant drugs, and 
several clinical studies suggested that changes in neuro-
active steroid concentrations might be involved in the 
pathophysiology and course of certain psychiatric disor-
ders. This review will in particular focus on the role of 
neuroactive steroids in depression and anxiety disor-
ders.
 Neuroactive Steroids as Endogenous Modulators of 
Depression and Anxiety Disorders 
 Pregnenolone, the main precursor molecule for steroid 
hormone and neuroactive steroid synthesis, and its sul-
fated derivate pregnenolone sulfate (PS) may directly 
modulate neurotransmitter receptors  [13] . Preclinical 
studies suggested that pregnenolone/PS modulate depres-
sion and anxiety-related behavior. PS has been shown to 
exert an antidepressant-like profile in the forced swim-
ming procedure, probably throughout interaction with    1  
receptors  [14] . In addition, in animal models of anxiety-
related behavior, a biphasic response curve has been shown 
for PS  [15] , being anxiogenic at higher and anxiolytic at 
lower doses  [15] . This effect is compatible with a demon-
strated mixed agonistic/antagonistic profile at GABA A  re-
ceptors  [16–18] . In line with these preclinical results, a 
pathophysiological role of pregnenolone and its sulfate 
conjugate has been suggested in affective disorders. De-
creased PS levels have been found in patients suffering 
from depression  [19] , generalized anxiety disorder  [20] 
and generalized social phobia  [21] . In contrast, in women 
suffering from mixed anxiety-depressive disorder  [22] or 
from premenstrual syndrome (PMS)  [23] , elevated PS 
plasma concentrations have been observed, suggesting 
that the pattern of dysregulated pregnenolone/PS levels 
may vary with different psychiatric disorders.
 Because of certain similarities concerning the molec-
ular mechanisms of PS and DHEA/DHEA sulfate 
(DHEAS), similar effects on depression and anxiety-re-
lated behavior might be expected. Like PS, also DHEAS 
has been shown to exert antidepressant-like effects in the 
forced swimming procedure, which are mediated 
throughout interaction with    1  receptors  [14, 24] . In ad-
dition, compatible with a positive allosteric modulation 
of GABA A  receptors at lower concentrations, DHEA/
DHEAS showed anxiolytic activity in the plus maze test 
in mice  [25] .
 In humans, a variety of studies focused on DHEA/
DHEAS plasma levels as an additional neuroendocrino-
logical marker of depression. However, these studies re-
vealed inconsistent results. In patients suffering from de-
pression, decreased DHEAS plasma levels  [26, 27] and 
DHEA salivary concentrations  [28] have been observed. 
In contrast, other studies reported significant elevations 
of DHEAS 24-hour urinary levels  [29] and diurnal mini-
mal and mean DHEA plasma concentrations  [30] .
 In addition, amelioration of depressive symptomatol-
ogy has been associated with a decrease in DHEA/DHEAS 
levels. In patients suffering from depression, elevated 
DHEAS plasma levels decreased after antidepressant 
pharmacotherapy  [31] . Furthermore, recently, remission 
of late-life depression has been associated with a decline 
in DHEA/DHEAS levels, an effect that was not observed 
in nonremitted patients  [28] . In line with these observa-
tions, elevated baseline concentrations of DHEAS have 
been shown to predict nonresponse to electroconvulsive 
therapy (ECT) in depressed psychotic patients  [32] .
 In line with a GABA-enhancing potential, anxiolytic 
effects of progesterone, the main precursor molecule for 
3  -reduced neuroactive steroids, have been shown in 
several preclinical trials. It has been suggested that the in 
vivo conversion of progesterone into 3  -pregnane ste-
roids accounts for its anxiolytic effects and not the direct 
interaction with intracellular progesterone receptors. 
Progesterone elicited anxiolytic effects in ovarectomized 
rats  [33] and in mice lacking intracellular progesterone 
receptors  [34] . These anxiolytic effects of progesterone 
were accompanied by an increase in 3  ,5  -THP concen-
trations  [33, 34] , suggesting that the anxiolytic properties 
of progesterone are mediated by its in vivo conversion to 
the 3  -reduced metabolite  [33] .
 In humans, a pathophysiological role of progesterone 
has been suggested in anxiety disorders. In women suf-
fering from panic disorder, an increase in progesterone 
levels has been reported during the midluteal phase of the 
menstrual cycle  [35] , where phobic symptomatology im-
proved significantly  [35] . Thus, the menstrual cycle-re-
lated surge of progesterone and its GABAergic metabo-
lites might contribute to the clinical amelioration of pan-
ic disorder  [35] . Furthermore, compared with healthy 
controls, progesterone plasma concentrations have been 
found to be elevated in drug-free male panic disorder pa-
tients and have been suggested to reflect a counterregula-
tory defense mechanism against the occurrence of panic 
attacks  [36] . In addition, progesterone plasma levels have 
been shown to correlate significantly with state anxiety 
scores in healthy males  [37] and in men suffering from 
panic disorder  [36] . However, no association has been 
found in women suffering from panic disorder  [35] , 
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thereby suggesting that the anxiety modulatory action of 
neuroactive steroids might depend on gender  [36] .
 In view of their GABA-enhancing properties, the ma-
jority of preclinical studies focused on possible anxio-
lytic properties of 3  -reduced neuroactive steroids. In 
different animal models of anxiety-related behavior, a 
clear anxiolytic profile has been shown for 3  ,5  -THP 
and 3  ,5  -THP  [38–43] . A similar anxiolytic potential 
has been demonstrated for the peripheral 3  -pregnane 
steroid 3  ,5  -THDOC  [41, 42, 44] . Although first stud-
ies investigating 3  -reduced neuroactive steroid levels in 
anxiety disorders found no differences in 3  ,5  -THP 
levels between patients suffering from mixed anxiety-de-
pressive disorder  [22] , generalized anxiety disorder  [20] 
or generalized social phobia  [45] and healthy controls, 
first studies of our research group in patients with panic 
disorder suggested that 3  -reduced neuroactive steroids 
may play a pivotal role in human anxiety.
 Compared with healthy controls, plasma concentra-
tions of 3  -reduced neuroactive steroids were elevated, 
while the concentrations of 3  ,5  -THP, an antagonistic 
stereoisomer of 3  ,5  -THP, were decreased  [46] . In line 
with this finding, in women suffering from panic disorder 
and agoraphobia, increased plasma concentrations of 
3  ,5  -THP have been observed during the early follicular 
and premenstrual phase  [35] . The observed elevations of 
3  -reduced neuroactive steroids and the concomitant de-
crease in the functional GABA-antagonistic isomer in 
panic disorder patients in the absence of panic attacks 
might be interpreted as endogenous counterregulatory 
mechanisms against the occurrence of spontaneous panic 
attacks  [47] . This hypothesis was further supported by 
our studies investigating neuroactive steroid concentra-
tions during experimental panic induction, which is a 
well-established model for the pathophysiology of panic 
disorder.
 Experimental panic induction was followed by pro-
nounced changes in neuroactive steroid concentrations, 
which were indeed the opposite to those seen in panic 
disorder patients in the absence of panic attacks. Chal-
lenge with sodium lactate or cholecystokinin-tetrapep-
tide (CCK-4) was accompanied by a significant decrease 
in 3  ,5  -THP and 3  ,5  -THP concentrations and a con-
comitant increase in 3  ,5  -THP levels in patients
with panic disorder  [48] , compatible with a decreased 
GABAergic tone during panic attacks. In contrast, no 
such changes in neuroactive steroid compositions follow-
ing challenge with sodium lactate or CCK-4 could be de-
tected in healthy controls  [48] , even if subjects exhibited 
a comparable level of CCK-4-induced panic anxiety  [49] . 
Therefore, the observed alterations in neuroactive steroid 
levels in patients with panic disorder during experimen-
tal panic induction do not merely reflect the level of anx-
iety but appear to be related to the pathophysiology of 
panic attacks in panic disorder  [48, 49] .
 However, panic induction with CCK-4, which is known 
to elicit a marked stimulation of cortisol and ACTH re-
lease  [50] , was accompanied by a significant rise in 3  ,5  -
THDOC levels in healthy controls  [51] ( fig. 2 ). As preclin-
ical data suggested a role for 3  ,5  -THDOC in the regula-
tion and termination of the endogenous stress response 
 [52] , the observed rise in 3  ,5  -THDOC levels might be a 
consequence of the CCK-4-induced ACTH release and 
might contribute to the termination of the panic/stress re-
sponse following challenge with CCK-4 in humans.
 In addition to the observed alterations in 3  -reduced 
neuroactive steroids in panic disorder, increasing evidence 
comes from preclinical and clinical studies that 3  -re-
duced neuroactive steroids play an important role as en-
dogenous modulators of major depression. In different an-
imal models of depression-related behavior, a dysregula-
tion of 3  -reduced neuroactive steroids has been observed, 
which has been suggested to constitute a pathophysiologi-
cal factor in the development of depression-related behav-
ior. Protracted social isolation in mice is followed by a be-
havioral adaptation syndrome and a decreased response to 
GABAergic drugs, which shares some features of depres-
sion. In the frontal cortex of such animals, the concentra-
tions of 3  ,5  -THP and 5  -DHP were decreased  [53, 54] 
due to a diminished expression of 5  -reductase type I pro-
tein and mRNA  [53] , suggesting that a dysregulated bio-
synthesis of 3  -reduced neuroactive steroids might con-
tribute to the behavioral and neurochemical alterations 
found in this mouse model of depression  [54, 55] .
 Olfactory bulbectomy represents a further rodent par-
adigm for depression. After olfactory bulbectomy, a sig-
nificant decline in 3  ,5  -THP levels has been observed 
in distinct cerebrocortical areas  [56] concurrently with 
the development of behavioral, neurochemical and neu-
roendocrine changes, which might contribute to the de-
velopment of the depression-related bulbectomy syn-
drome  [56] . Thus, the decline in 3  ,5  -THP levels might 
reflect a distinct pathophysiological mechanism underly-
ing the depression-related behavioral alterations in the 
bulbectomy syndrome  [56] .
 In line with these preclinical investigations, alterations 
in 3  -pregnane neuroactive steroids have been observed 
in humans suffering from major depression. In two inde-
pendent samples of depressive patients, decreased levels of 
3  -reduced neuroactive steroids have been found both in 
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plasma  [57] and in cerebrospinal fluid (CSF)  [58] . The 
concentrations of 3  ,5  -THP and 3  ,5  -THP were re-
duced in plasma and CSF, while there was an increase in 
3  ,5  -THP, which may act as a functional antagonist for 
those GABA-agonistic steroids  [57] . Furthermore, 3  ,5  -
THDOC plasma levels were found to be elevated during 
depression, probably as a consequence of hypothalamic-
pituitary-adrenal axis overdrive  [59] .
 Therapeutic Potential of Neuroactive Steroids in 
the Treatment of Major Depression and Anxiety 
Disorders 
 Therapeutic Properties of Synthetic Derivates of 
Neuroactive Steroids 
 Corresponding to preclinical data suggesting antide-
pressive and anxiolytic effects of exogenously adminis-
tered pregnenolone and PS, first clinical investigations 
evaluated the putative therapeutical effects of pregneno-
lone in humans. Although the first study in healthy volun-
teers revealed no improvement in mood, memory, self-rat-
ed sleep quality or subjective well-being after 4 weeks of 
treatment with pregnenolone  [60] , a tendency for pregnen-
olone to reduce subjective depression ratings was observed 
 [60] . Furthermore, in an additional subgroup analysis, 
pregnenolone significantly reduced the sedative effects of 
a single dose of diazepam  [60] . In this context, it was hy-
pothesized that pregnenolone, due to its GABA A  receptor 
antagonistic profile, might antagonize acute benzodiaze-
pine effects, and therefore, might be of putative benefit for 
the treatment of certain psychiatric conditions  [60] .
 In line with observed alterations in DHEA/DHEAS 
levels in depressed patients, first studies investigating the 
therapeutical effects of DHEA revealed promising results 
in the treatment of major depression. Already the first 
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 Fig. 2. Panic response (acute panic inventory score; API) ( a ) and plasma concentrations of ACTH ( b ), 3  ,5  -
THDOC ( c ) and cortisol ( d ) in healthy controls before (–1 min) and after experimental panic induction with 
50   g CCK-4 (10–20 min after challenge). Data are presented as mean ± SEM. * Statistical significance at the
p < 0.05 level in post hoc tests following MANOVA. Reproduced with permission from Eser et al.  [51] . 
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open-label study demonstrated a significant improve-
ment in depressive symptoms after 6 months of DHEA 
therapy  [61] . Further double-blind placebo-controlled 
trials confirmed these results. In midlife-onset dysthy-
mia, 60% of the patients responded to treatment with 
DHEA after 6 weeks  [62] . Furthermore, administration 
of DHEA either as a monotherapy or as an augmentation 
to stable antidepressant regimens significantly decreased 
depressive symptoms in unipolar and bipolar depression 
 [63] . Recently, it has been demonstrated that even mono-
therapy with DHEA significantly improved symptoms of 
minor and major midlife-onset depression  [64] .
 So far, putative therapeutic properties of DHEAS have 
not been investigated in anxiety disorders. However, in 
schizophrenic patients additionally treated with DHEA, 
anxiety symptoms improved  [65] , thereby suggesting 
that this neurosteroid may also possess beneficial effects 
in the treatment of anxiety-related symptoms.
 Clinical studies concerning putative therapeutical ef-
fects of progesterone in major depression or anxiety dis-
orders are lacking so far. Nevertheless, administration of 
progesterone might constitute a supplementary treat-
ment strategy for several clinical symptoms found in de-
pression, as progesterone exerts pronounced GABAergic 
effects on sleep  [66] . In addition, several studies focused 
on the putative beneficial effects of progesterone admin-
istration in patients suffering from PMS, which in part 
overlaps with depressive symptomatology. While some 
investigations reported an improvement in mood  [67–69] 
in women suffering from PMS, others found no superior-
ity to placebo treatment  [70–72] . Furthermore, the previ-
ously recommended prophylactic postpartum use of pro-
gesterone in women who had experienced postpartum 
depression in the past  [73] was challenged by an observed 
enhanced risk of postpartum depression after progester-
one therapy  [74] . Thus, no definite conclusion can be 
drawn at the moment as to whether or not synthetic pro-
gestins might constitute a useful strategy for the treat-
ment of anxiety or depression  [75] .
 Modulation of Endogenous Neuroactive Steroid 
Levels as a Putative Pharmacological Mechanism of 
Antidepressant Drugs 
 Preclinical studies suggested that neuroactive steroids 
may not only directly modulate anxiety and depression-
related behavior but that neuroactive steroids may also be 
involved in the therapeutical effects of antidepressant 
drugs. Most evidence for this suggestion came from stud-
ies investigating the impact of antidepressant treatment 
on endogenous 3  -reduced neuroactive steroid levels.
 In the depression-related olfactory bulbectomy model, 
chronic treatment with three different classes of antide-
pressants reversed the decline in 3  ,5  -THP levels in rats 
after 3 weeks  [76] . This time interval is typically neces-
sary to counteract the depression-related behavioral def-
icits of the bulbectomy syndrome by pharmacological 
treatment  [76] . Therefore, it has been suggested that nor-
malization of 3  ,5  -THP levels might contribute to the 
therapeutic effects of various antidepressants in this ani-
mal model of depression  [76] . However, the molecular 
mechanisms underlying the effects of antidepressant 
drugs on neuroactive steroid concentrations are still un-
der investigation.
 Acute administration of the selective serotonin reup-
take inhibitor (SSRI) fluoxetine in rats was followed by a 
significant increase in 3  ,5  -THP in different brain re-
gions  [77, 78] and a concomitant decrease in the precur-
sor molecule 5  -DHP  [77] . In contrast, the tricyclic anti-
depressant imipramine had no effect on neuroactive ste-
roid concentrations  [77] , suggesting a specific action of 
fluoxetine on 3  -hydroxysteroid dehydrogenase (3  -
HSD), the enzyme that catalyses the conversion of 5  -
DHP to 3  ,5  -THP  [77] . This hypothesis was supported 
by the finding that SSRIs but not tricyclic antidepressants 
shift the activity of the 3  -HSD towards the reductive 
direction  [79] , thereby enhancing the efficiency of the 
conversion of 5  -DHP to 3  ,5  -THP  [79] , although 
these findings were not confirmed in another study  [80] . 
Furthermore, preclinical studies investigating the effects 
of mirtazapine on neuroactive steroid composition re-
vealed conflicting results. Mirtazapine is an antidepres-
sant which acts as an antagonist of    2 ,5-HT 2 ,5-HT 3  and 
histamine H 1  receptors, a mechanism different from 
 SSRIs and tricyclic antidepressants. Single injections of 
mirtazapine increased 3  ,5  -THP brain and plasma lev-
els, while mirtazapine long-term administration did not 
affect neuroactive steroid levels  [81] . However, recently, 
we were able to demonstrate a dose-dependent inhibitory 
effect of mirtazapine on the activity of a microsomal 3  -
HSD  [82] . Although 3  -HSD can act bidirectionally in 
vitro, in the living brain, due to the intracellular avail-
ability of respective cofactors, cytosolic 3  -HSD is ex-
pected to almost exclusively catalyze the conversion of 
5  -DHP into 3  ,5  -THP (reductive pathway), whereas 
microsomal 3  -HSD is expected to catalyze the conver-
sion of 3  ,5  -THP into 5  -DHP (oxidative pathway) 
 [82] . Mirtazapine did not affect the reductive direction 
but inhibited a microsomal isoform of 3  -HSD, thereby 
 Eser  /Schüle  /Baghai  /Romeo  /Rupprecht  
 
Neuroendocrinology 2006;84:244–254250
inhibiting the oxidation of 3  ,5  -THP into 3  -DHP 
( fig. 3 ). This effect is compatible with an enhanced for-
mation of 3  -reduced neuroactive steroids similar to the 
effect of SSRIs  [82] .
 In depressed patients, a variety of studies suggested 
that antidepressant drugs might correct the observed dis-
equilibrium in 3  -reduced neuroactive steroid composi-
tion and that this correction might contribute to the ther-
apeutical effects of antidepressant drugs. Administration 
of fluoxetine has been shown to increase 3  ,5  -THP and 
3  ,5  -THP plasma  [57] and CSF levels  [58] and to con-
comitantly decrease 3  ,5  -THP concentrations in pa-
tients suffering from depression  [57] . However, in con-
trast to preclinical data, treatment with tricyclic antide-
pressants influenced 3  ,5  -THP, 3  ,5  -THP and 
3  ,5  -THP levels in a similar way to SSRIs  [57] .
 To answer the question whether changes in neuroac-
tive steroid concentrations contribute to the clinical ef-
fects of antidepressant treatment or whether they are re-
lated to specific pharmacological properties of antide-
pressant drugs, our group investigated the impact of 
different nonpharmacological treatment strategies on 
neuroactive steroid concentrations in major depression.
 Partial sleep deprivation (PSD), which is known to 
rapidly but only transiently ameliorate depressive symp-
toms, was applied in depressed inpatients as a monother-
apy. Neuroactive steroid levels were determined the day 
before and after PSD and after one night of recovery sleep 
 [83] . PSD ameliorated depressive symptoms in the major-
ity of patients, although this therapeutical effect was only 
transient and followed by a relapse of symptoms the day 
after recovery sleep. Nonresponders compared with re-
sponders showed significantly higher plasma concentra-
tions of 3  ,5  -THP and 3  ,5  -THP before and after 
PSD; however, no alterations in neuroactive steroid levels 
could be detected after PSD in either group  [83] .
 In addition, we investigated the impact of repetitive 
transcranial magnetic stimulation (rTMS) as a medium-
term nonpharmacological treatment strategy  [84] . How-
ever, even though about half of the patients significantly 
improved after 2 weeks of rTMS monotherapy, no alter-
ations in 3  ,5  -THP, 3  ,5  -THP and 3  ,5  -THP levels 
could be found either in responders or nonresponders 
 [84] , suggesting that the antidepressive effects of this me-
dium-term biological treatment strategy are not linked to 
alterations in 3  -reduced neuroactive steroid levels. Fi-
nally, to rule out the possibility that the antidepressive 
effects of PSD or rTMS may have been too weak to inter-
fere with neuroactive steroid concentrations, the impact 
of ECT was studied on neuroactive steroids. ECT is still 
considered as the most effective biological treatment 
strategy in severe treatment-resistant major depression. 
Neuroactive steroids were quantified in 31 pharmaco-
therapy-resistant depressed patients before and after 4 
weeks of ECT  [85] . Sixteen out of 31 patients responded 
to ECT and about half of those patients achieved a full 
remission from major depression. However, remitters, re-
sponders and nonresponders did not differ in neuroac-
tive steroid levels nor did ECT influence 3  ,5  -THP, 
3  ,5  -THP and 3  ,5  -THP concentrations  [85] .
 Therefore, in contrast to the previously reported 
changes in 3  -reduced neuroactive steroid concentra-
tions following antidepressant pharmacotherapy, none of 
the investigated nonpharmacological treatment strate-
gies had any impact on neuroactive steroid levels despite 
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a pronounced antidepressive effect. These findings con-
firmed the hypothesis that the observed alterations in 
neuroactive steroid concentrations following antidepres-
sant pharmacotherapy are indeed related to specific phar-
macological properties of antidepressant drugs.
 Furthermore, our research group recently investigated 
the impact of mirtazapine monotherapy on neuroactive 
steroid composition in patients suffering from major de-
pression. We found increased 3  ,5  -THP, 3  ,5  -THP, 
5  -DHP and 5  -DHP concentrations, whereas 3  ,5  -
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THP levels decreased after 5 weeks of mirtazapine mono-
therapy  [82] . However, these changes in neuroactive ste-
roid concentrations were comparable in responders and 
nonresponders and were not correlated to the clinical re-
sponse ( fig. 4 ). Therefore, so far, our data do not support 
the hypothesis that the normalization of endogenous 
neuroactive steroid levels is essential for the clinical re-
sponse in the treatment of depression, and a lack of effect 
on neuroactive steroid concentrations, as noted after 
nonpharmacological treatment, does not preclude anti-
depressive efficacy.
 Nevertheless, the interference with neuroactive ste-
roid composition still constitutes a promising new phar-
macological treatment strategy in depression and anxiety 
disorders as preclinical data suggested beneficial effects 
of new mitochondrial benzodiazepine receptor (MBR) li-
gands. The biosynthesis of GABAergic neuroactive ste-
roids, which is under the control of the MBR  [86] , might 
be enhanced throughout treatment with specific MBR 
agonists  [86] , and these MBR agonists have been shown 
to exert pronounced anxiolytic effects in animal models 
without sedation and abuse liability  [86, 87] .
 Conclusion 
 There is considerable preclinical and clinical evidence 
that neuroactive steroids are important endogenous 
modulators of depression and anxiety-related behavior 
and might have therapeutic potential for the treatment of 
depression and anxiety disorders. A definitive proof 
whether neuroactive steroids have indeed a therapeutical 
potential for the treatment of affective disorders and are 
superior to already existing psychopharmacological 
drugs will come from systematic clinical studies in this 
new area of research. Such novel therapeutic strategies 
might either be based on synthetic derivates of endoge-
nous neuroactive steroids or on the modulation of neuro-
steroid synthesis either by classical antidepressants or 
other compounds interfering with neurosteroidogenic 
enzymes. Additionally, the peripheral benzodiazepine 
receptor may constitute a further target to influence the 
equilibrium of endogenous neuroactive steroids.
 Furthermore, it remains to be elucidated whether neu-
roactive steroids may serve as biomarkers in the differen-
tial diagnosis of affective disorders. However, in this con-
text, it has to be determined to what extent neuroactive 
steroid plasma levels essentially reflect brain concentra-
tions. Although it has been suggested that plasma levels 
are likely to reflect brain levels, because neuroactive ste-
roids can easily cross the blood brain barrier, this does 
not exclude the possibility of local alterations in brain 
concentrations of neuroactive steroids that are not de-
tected by plasma or CSF measurements. Therefore, fur-
ther research is needed to develop highly sensitive and 
specific technologies of neurosteroid determination, 
which are both economical and of reasonable labor inten-
sity.
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